EANM Thyroid Committee, Vienna, Austria -
Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia -
Q J Nucl Med Mol Imaging. 2022 Jun;66(2):93-103. doi: 10.23736/S1824-4785.22.03427-6. Epub 2022 Feb 15.
Parathyroid imaging is essential for the detection and localization of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (pHPT). Surgical treatment of pHPT mainly consists of minimally invasive parathyroidectomy (MIP), as a single adenoma represents the most common cause of this endocrine disorder. Successful surgery requires an experienced surgeon and relies on the correct preoperative detection and localization of hyperfunctioning parathyroid glands. Failure to preoperatively identify the culprit parathyroid gland by imaging may entail a more invasive surgical approach, including bilateral open neck exploration, with higher morbidity compared to minimally invasive parathyroidectomy. Parathyroid imaging may be also useful before surgery in case of secondary hyperparathyroidism (sHPT) or hereditary disorders (MEN 1, 2, 4) as it enables correct localization of typically located parathyroid glands, detection of ectopic as well as supernumerary glands. It is now accepted by most surgeons experienced in parathyroid surgery that preoperative imaging plays a key role in their patients' management. Recently, the European Association of Nuclear Medicine (EANM) issued an updated version of its Guidelines on parathyroid imaging. Its aim is to precise the role and the advantages and drawbacks of the various imaging modalities proposed or well established in the preoperative imaging strategy. It also aims to favor high performance in indicating, performing, and interpreting those examinations. The objective of the present article is to offer a summary of those recent EANM Guidelines and their originality among other Guidelines in this domain issued by societies of nuclear medicine physicians or other disciplines.
甲状旁腺成像对于原发性甲状旁腺功能亢进症(pHPT)患者中功能性甲状旁腺组织的检测和定位至关重要。pHPT 的手术治疗主要包括微创甲状旁腺切除术(MIP),因为单个腺瘤是这种内分泌紊乱的最常见原因。成功的手术需要有经验的外科医生,并且依赖于术前正确检测和定位功能性甲状旁腺。如果术前影像学未能识别出致病的甲状旁腺,可能需要更具侵袭性的手术方法,包括双侧开放性颈部探查,与微创甲状旁腺切除术相比,其发病率更高。甲状旁腺成像在继发性甲状旁腺功能亢进症(sHPT)或遗传性疾病(MEN 1、2、4)的术前也可能有用,因为它可以正确定位通常位于甲状旁腺的位置,检测异位和多余的腺体。现在,大多数有甲状旁腺手术经验的外科医生都认为术前成像在患者的管理中起着关键作用。最近,欧洲核医学协会(EANM)发布了其甲状旁腺成像指南的更新版本。其目的是明确各种成像方式的作用以及在术前成像策略中提出或成熟的优势和缺点。它还旨在促进这些检查的指示、执行和解释的高性能。本文的目的是总结这些最近的 EANM 指南及其在该领域由核医学医师或其他学科协会发布的其他指南中的创新性。